Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-000220-16 | EudraCT Number | ||
| U1111-1119-4743 | Registry Identifier | WHO | |
| 11-028 | Registry Identifier | ROCTR | |
| NL36272.072.11 | Registry Identifier | CCMO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg), once daily, in participants with grades 2 or 3 essential hypertension who do not reach target blood pressure following treatment with 40 mg azilsartan medoxomil monotherapy after 4 weeks.
Eligible participants completed a 2-week single-blind run-in period (Days -42 to -29) prior to a Single-Blind Monotherapy Treatment Period (Day -28 to Day -1) where they received azilsartan medoxomil 40 mg. After the Single-Blind Monotherapy Treatment Period, those participants who achieved target blood pressure discontinued treatment and resumed standard of care management at the discretion of their treating physician, while those participants who did not achieve target blood pressure (defined as clinic systolic blood pressure ≥140 mmHg) were randomly assigned to 1 of 3 active treatment arms: azilsartan medoxomil 40 mg plus placebo, azilsartan medoxomil plus chlorthalidone 40/12.5 mg, or azilsartan medoxomil plus chlorthalidone 40/25 mg.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Azilsartan medoxomil 40 mg | Active Comparator | Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks. |
|
| Azilsartan medoxomil + chlorthalidone 40/12.5 mg | Experimental | Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks. |
|
| Azilsartan medoxomil + chlorthalidone 40/25 mg | Experimental | Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Azilsartan medoxomil/placebo | Drug | Azilsartan medoxomil and placebo to chlorthalidone combination tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure | The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. | Baseline (of the double-blind treatment period) and Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure | The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. | Baseline and Week 8 |
Not provided
Inclusion Criteria:
At Screening
The participant has grade 2-3 essential hypertension which is not adequately controlled, as defined by mean, trough, sitting, clinic systolic blood pressure (SBP):
The participant has clinical laboratory test results (clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the investigator does not consider the results to be clinically relevant for precluding entry in to the study in this hypertensive population.
The participant is willing to discontinue current antihypertensive medications.
In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Male or female adult, at least 18 years of age.
A female of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from signing of the informed consent through 30 days after the last study drug dose. NOTE: Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation [performed more than one 1 year prior to Screening]) or who are postmenopausal (defined as at least 1 year since last regular menses).
Post-placebo run-in:
The participant must have a post-placebo run-in, 24-hour mean SBP by ambulatory blood pressure monitoring (ABPM) of 140-175 mm Hg inclusive, and a clinic SBP measurement of 160 to 190 mm Hg inclusive (determined by the mean of 3 sitting, trough, measurements on Day -29) to qualify for entry in to the 4 week single-blind TAK-491 40 mg monotherapy treatment period.
Post-4 week, single-blind TAK-491 40 mg monotherapy treatment:
The participant does not achieve target blood pressure (defined as clinic SBP ≥140 mm Hg as determined by the mean of 3 sitting, trough, measurements) following 4 weeks single-blind treatment with TAK-491 40 mg monotherapy at Day -1, prior to randomization to double-blind treatment.
Exclusion Criteria:
At Screening
The participant has clinic diastolic blood pressure (DBP) >110 mm Hg.
The participant's 3 SBP measurements differ by more than 15 mm Hg (confirmed by a second set of three measurements).
The participant has received any investigational compound within 30 days prior to Screening or is currently participating in another investigational study. NOTE: Participants participating in observational studies (per local definition) may enter Screening provided that the last intervention or invasive procedure was >30 days prior to Visit 1.
The participant has been randomized/enrolled in a previous TAK-491 or TAK-491CLD study. NOTE: This criterion does not apply to participants who entered screening or placebo run-in in another TAK-491 or TAK-491CLD study but were not randomized/enrolled.
The participant is a study site employee or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
The participant is currently treated with more than 2 antihypertensive medications.
The participant works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]).
The participant has an upper arm circumference <24 cm or >42 cm.
The participant has secondary hypertension of any etiology (e.g., renovascular disease, pheochromocytoma, Cushing's syndrome).
The participant has any history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, persistent or permanent atrial fibrillation or transient ischemic attack.
The participant has clinically significant cardiac conduction defects (e.g., third-degree atrioventricular block, sick sinus syndrome).
The participant has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease or hypertrophic cardiomyopathy.
The participant has severe renal dysfunction or disease [based on estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m^2 at screening], prior renal transplantation or nephrotic syndrome (defined as a urinary albumin/creatinine ratio >2000 mg/g at Screening).
Participant has known hemodynamically significant bilateral renal artery stenosis or unilateral disease in a single kidney.
The participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of single-blind TAK-491 monotherapy study drug. (This criterion does not apply to those participants with basal cell or Stage 1 squamous cell carcinoma of the skin).
The participant has poorly-controlled type 1 or 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.5%) at Screening.
The participant has hypokalemia or hyperkalemia (defined as serum potassium outside of the normal reference range of the central laboratory) at Screening.
The participant has an alanine aminotransferase or aspartate aminotransferase level >2.5 times the upper limit of normal, active liver disease, or jaundice at Screening.
The participant has any other known serious disease or condition that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow the participant according to the protocol.
The participant has a history of hypersensitivity or allergies to angiotensin II receptor blockers (ARB) or thiazide-type diuretics or other sulfonamide-derived compounds.
The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse per local guidelines within the past 2 years.
The participant is required to take excluded medications at any point during the study.
If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
Post-placebo run-in period
The participant has a clinic SBP >190 mm Hg and DBP >115 mm Hg.
The participant is noncompliant (<70% or >130%) with study medication during the placebo run-in period.
The participant has a 24-hour mean eligibility ABPM reading of insufficient quality.
Post-single-blind TAK-491 40 mg treatment period
The participant has a clinic SBP >180 mm Hg and DBP >110 mm Hg.
The participant is noncompliant (<70% or >130%) with study medication during the TAK-491 40 mg single-blind treatment period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director, Clinical Science | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Haskovo | Bulgaria | |||||
507 participants entered the azilsartan medoxomil 40 mg Single-Blind Monotherapy Treatment Period and 395 participants were eligible to enter the Double-Blind Treatment Period and were randomly assigned to 1 of 3 active treatment arms.
A total of 1754 patients were screened at 125 investigative sites in Bulgaria, Estonia, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Serbia, Slovakia, Spain, Sweden, and the United Kingdom from 31 October 2011 to 24 January 2013.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Azilsartan Medoxomil 40 mg | Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks. |
| FG001 | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Azilsartan medoxomil - chlorthalidone | Drug | Azilsartan medoxomil and chlorthalidone fixed dose combination tablets |
|
|
| Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring |
The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. |
| Baseline and Week 8, 22-24 hours after dosing |
| Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. | Baseline and Week 8, 22-24 hours after dosing |
| Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. | Baseline and Week 8 |
| Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. | Baseline and Week 8 |
| Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. | Baseline and Week 8 |
| Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. | Baseline and Week 8 |
| Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. | Baseline and Week 8 |
| Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. | Baseline and Week 8. |
| Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring | The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. | Baseline and Week 8 |
| Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring | The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. | Baseline and Week 8 |
| Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8 | Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements. | Week 8 |
| Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8 | Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. | Week 8 |
| Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8 | Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure. | Week 8 |
| Pazardzhik |
| Bulgaria |
| Pleven | Bulgaria |
| Plovdiv | Bulgaria |
| Sofia | Bulgaria |
| Varna | Bulgaria |
| Veliko Tarnovo | Bulgaria |
| Paide | Estonia |
| Saku | Estonia |
| Tallinn | Estonia |
| Tartu | Estonia |
| Võru | Estonia |
| Labarthe-sur-Lèze | Haute Garonne | France |
| Bourg-des-Comptes | Ille et Vilaine | France |
| Tours | Indre et Loire | France |
| Vourey | Isere | France |
| Saint-Étienne-de-Montluc | Pays de la Loire Region | France |
| Orthez | Pyrenees Atlantiques | France |
| Karlsruhe | Baden-Wurttemberg | Germany |
| Bad Wörishofen | Bavaria | Germany |
| Nuremberg | Bavaria | Germany |
| Hamburg | Free and Hanseatic City of Hamburg | Germany |
| Frankfurt am Main | Hesse | Germany |
| Stuhr | Lower Saxony | Germany |
| Essen | North Rhine-Westphalia | Germany |
| Kamp-Lintfort | North Rhine-Westphalia | Germany |
| Mainz | Rhineland-Palatinate | Germany |
| Dresden | Saxony | Germany |
| Budapest | Hungary |
| Debrecen | Hungary |
| Gyöngyös | Hungary |
| Gyula | Hungary |
| Mosonmagyaróvár | Hungary |
| Nyíregyháza | Hungary |
| Pécs | Hungary |
| Szikszó | Hungary |
| Torrette Di Ancona | Ancona | Italy |
| Acquaviva delle Fonti | Bari | Italy |
| Brescia | Brescia | Italy |
| Ferrara | Ferrara | Italy |
| L’Aquila | L'Aquila | Italy |
| Milan | Milano | Italy |
| Palermo | Palermo | Italy |
| Pavia | Pavia | Italy |
| Pisa | Pisa | Italy |
| Roma | Roma | Italy |
| Sassari | Sassari | Italy |
| Legnago | Verona | Italy |
| Bologna | Italy |
| Alytus | Lithuania |
| Kaunas | Lithuania |
| Beek | Netherlands |
| Breda | Netherlands |
| Eindhoven | Netherlands |
| Groningen | Netherlands |
| Leiderdorp | Netherlands |
| Maastricht | Netherlands |
| Rotterdam | Netherlands |
| Velp | Netherlands |
| Zoetermeer | Netherlands |
| Zwijndrecht | Netherlands |
| Bydgoszcz | Poland |
| Gdansk | Poland |
| Gdynia | Poland |
| Krakow | Poland |
| Lodz | Poland |
| Lublin | Poland |
| Oświęcim | Poland |
| Parczew | Poland |
| Poznan | Poland |
| Pulway | Poland |
| Rzeszów | Poland |
| Sopot | Poland |
| Torun | Poland |
| Zgierz | Poland |
| Belgrade | Serbia |
| Kamenitz | Serbia |
| Kragujevac | Serbia |
| Kruševac | Serbia |
| Niš | Serbia |
| Zemun | Serbia |
| Bardejov | Slovakia |
| Bratislava | Slovakia |
| Galanta | Slovakia |
| Komárno | Slovakia |
| Košice | Slovakia |
| Lučenec | Slovakia |
| Martin | Slovakia |
| Nitra | Slovakia |
| Nové Zámky | Slovakia |
| Prešov | Slovakia |
| Svidník | Slovakia |
| Žilina | Slovakia |
| Barcelona | Barcelona | Spain |
| Centelles | Barcelona | Spain |
| Madrid | Madrid | Spain |
| Málaga | Malaga | Spain |
| Gothenburg | Sweden |
| Lund | Sweden |
| Malmö | Sweden |
| Vällingby | Sweden |
| London | Greater London | United Kingdom |
| Glasgow | Lanarkshire | United Kingdom |
| Blackpool | Lancashire | United Kingdom |
| Northwood | Middlesex | United Kingdom |
| Bath | Somerset | United Kingdom |
| Royal Leamington Spa | Warwickshire | United Kingdom |
| Westbury | Wiltshire | United Kingdom |
Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
| FG002 | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Participants who were randomized into the double-blind treatment period. Baseline was defined as the last observed value while on monotherapy study drug and before the first dose of double-blind study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Azilsartan Medoxomil 40 mg | Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks. |
| BG001 | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks. |
| BG002 | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Age, Customized | Number | participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Participants could choose more than 1 category for race and those who indicated more than 1 race category were included in each category and in the Multiracial category. Thus the total number of participants may not generally add up to the total number of each group. | Number | participants |
| |||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| Weight | Mean | Standard Deviation | kg |
| |||||||||||||||
| Height | Height data only available for 126 participants in the Azilsartan medoxomil + chlorthalidone 40/12.5 mg treatment group. | Mean | Standard Deviation | cm |
| ||||||||||||||
| Body Mass Index (BMI) | BMI data only available for 126 participants in the Azilsartan medoxomil + chlorthalidone 40/12.5 mg treatment group. | Mean | Standard Deviation | kg/m^2 |
| ||||||||||||||
| Smoking Classification | Number | participants |
| ||||||||||||||||
| Diabetes Status | Number | participants |
| ||||||||||||||||
| Estimated Glomerular Filtration Rate (eGFR) | Mean | Standard Deviation | mL/min/1.73 m^2 |
| |||||||||||||||
| Baseline eGFR Categories (mL/min/1.73 m^2) | Number | participants |
| ||||||||||||||||
| Trough Clinic Systolic Blood Pressure (SBP) | Mean | Standard Deviation | mmHg |
| |||||||||||||||
| Trough Clinic SBP Category (mmHg) | Number | participants |
| ||||||||||||||||
| Trough Clinic Diastolic Blood Pressure (DBP) | Mean | Standard Deviation | mmHg |
| |||||||||||||||
| Trough Clinic DBP Categories (mmHg) | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure | The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. | Full analysis set, consisting of all randomized participants who received at least 1 dose of double-blind study drug. A participant was included in the analyses only when there was both a baseline value and at least 1 value during the double-blind treatment period. Last observation carried forward (LOCF) was used. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline (of the double-blind treatment period) and Week 8 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure | The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. | Full analysis set; LOCF was used. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. | Full analysis set. Only participants with a baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8, 22-24 hours after dosing |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring | The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8, 22-24 hours after dosing |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring | The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring | The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring | The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. | Full analysis set. Only participants with a Baseline and at least 1 post-baseline value of acceptable quality were included. | Posted | Least Squares Mean | Standard Error | mm Hg | Baseline and Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8 | Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements. | Full analysis set | Posted | Number | percentage of participants | Week 8 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8 | Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. | Full analysis set | Posted | Number | percentage of participants | Week 8 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8 | Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure. | Full analysis set | Posted | Number | percentage of participants | Week 8 |
|
For 4 weeks during the monotherapy treatment period and from the first dose of double-blind study drug up to 14 days (or 30 days for a Serious AE) after the last dose of study drug in the 8-week double-blind treatment period.
The investigator documented any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of relation to study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Monotherapy: Azilsartan Medoxomil 40 mg | Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for 4 weeks during the Single-Blind Monotherapy Treatment Period. All enrolled participants, including those who were not randomized to double-blind treatment are included in this group. | 3 | 507 | 15 | 507 | ||
| EG001 | Azilsartan Medoxomil 40 mg | Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks during the Double-Blind Treatment Period. | 2 | 133 | 15 | 133 | ||
| EG002 | Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg | Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks during the Double-Blind Treatment Period. | 0 | 127 | 13 | 127 | ||
| EG003 | Azilsartan Medoxomil + Chlorthalidone 40/25 mg | Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks during the Double-Blind Treatment Period. | 0 | 135 | 26 | 135 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Myocardial infarction | Cardiac disorders | MedDRA version 15.1 | Systematic Assessment |
| |
| Cerebrovascular accident | Nervous system disorders | MedDRA version 15.1 | Systematic Assessment |
| |
| Acute myocardial infarction | Cardiac disorders | MedDRA version 15.1 | Systematic Assessment |
| |
| Ventricular tachycardia | Cardiac disorders | MedDRA version 15.1 | Systematic Assessment |
| |
| Blood pressure increased | Investigations | MedDRA version 15.1 | Systematic Assessment |
| |
| Renal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA version 15.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nasopharyngitis | Infections and infestations | MedDRA version 15.1 | Systematic Assessment |
| |
| Viral infection | Infections and infestations | MedDRA version 15.1 | Systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA version 15.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA version 15.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA version 15.1 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA version 15.1 | Systematic Assessment |
|
The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sr. VP, Clinical Science | Takeda GlobalResearch and Development Center, Inc. | 800-778-2860 | clinicaltrialregistry@tpna.com |
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C557413 | azilsartan medoxomil |
| C521273 | azilsartan |
Not provided
Not provided
Not provided
| 45 to < 65 years |
|
| ≥ 65 years |
|
| Male |
|
| Asian |
|
| Black or African American |
|
| Native Hawaiian or Other Pacific Islander |
|
| White |
|
| Multiracial |
|
| Estonia |
|
| France |
|
| Germany |
|
| Hungary |
|
| Italy |
|
| Lithuania |
|
| Netherlands |
|
| Poland |
|
| Serbia |
|
| Slovakia |
|
| Spain |
|
| Sweden |
|
| United Kingdom |
|
| Current smoker |
|
| Ex-smoker |
|
| No |
|
| 60 to < 90 ml/min/1.73 m^2 |
|
| ≥ 90 ml/min/1.73 m^2 |
|
| ≥140 - <160 mmHg |
|
| ≥160 - <180 mmHg |
|
| ≥180 mmHg |
|
| ≥90 mmHg |
|
|
| ANCOVA | ANCOVA model with treatment as a fixed effect and baseline trough, sitting, clinic SBP as a covariate | <0.001 | LS mean difference | -9.5 | 2-Sided | 95 | -12.4 | -6.5 | No | Superiority or Other |
| Participants |
|
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|